Impact of disease manifestations on first biologic drug survival in axial spondyloarthritis: a real-life Canadian study.

ABSTRACT:

Objectives

The primary objective of this study was to assess the impact of extramusculoskeletal manifestations (EMMs) and peripheral musculoskeletal features on first biologic drug survival in subjects with axial spondyloarthritis (axSpA). The secondary objective was to evaluate the impact of reasons for treatment discontinuation.

Methods

A total of 593 axSpA patients from the SpondyloArthritis Research Consortium of Canada initiating a first biologic drug were identified between 2003 and 2023. Drug survival was presented using Kaplan-Meier curves for each disease manifestation and compared using the logrank test. A Cox proportional hazards model was used to analyse independent predictors of discontinuation. The impact of reasons for treatment discontinuation was assessed us

SUBMITTER: Hurtubise R 

PROVIDER: S-EPMC11780884 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature